PharmaCyte Biotech, Inc. (PMCB) Cash Flow Statement
Where PMCB’s cash came from and went, FY2026
April 30, 2026 · U.S. dollars- Cash from operations
- −$5.2M
- Capital expenditures
- $0
- Free cash flow
- −$5.2M
- Returned to shareholders
- $647,630
- Change in cash
- $3.4M cash at year-end $18.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
PMCB operating cash flow, capex and free cash flow
PMCB cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$3.3MFY2017 | −$5.2MFY2026 | — | |
| Capital expenditures | $0FY2017 | $0FY2026 | — | |
| Free cash flow | −$3.3MFY2017 | −$5.2MFY2026 | — | |
| Operating cash flow / net income | −6.45FY2024 | −0.10FY2025 | +6.35 | |
| Stock-based compensation | $1.0MFY2017 | $1.1MFY2026 | +1.2%/yr | |
| Dividends paid | $22.5MFY2024 | $246,005FY2026 | −89.5%/yr | |
| Share buybacks (net) | $0FY2017 | $401,625FY2026 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PMCB cash flow by activity
PMCB net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PMCB cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$19.4M | $30.7M | $333,763 | −$4.3M | −$4.2M | −$3.6M | −$3.8M | −$4.1M | −$6.8M | −$4.4M |
| Depreciation & amortization | — | — | — | — | — | — | — | — | — | $4.4M |
| Stock-based compensation | $1.1M | $478,637 | $674,693 | $645,406 | $77,956 | $370,829 | $748,027 | $705,678 | $1.5M | $1.0M |
| Change in working capital | −$1.9M | $1.4M | $298,894 | −$297,166 | $9,040 | −$145,608 | $267,349 | $167,099 | −$85,873 | −$21,157 |
| Other non-cash items | $15.1M | −$35.5M | −$3.5M | $174,022 | $34,846 | −$4,874 | $473,139 | $316,539 | $309,881 | −$4.3M |
| Cash from operating activities | −$5.2M | −$3.0M | −$2.2M | −$3.8M | −$4.1M | −$3.3M | −$2.3M | −$2.9M | −$5.1M | −$3.3M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$4 | −$3 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | −$3.0M | −$7.0M | −$5.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions & other investing | $5.0M | $4 | $3 | — | — | — | — | — | — | — |
| Cash from investing activities | $2.0M | −$7.0M | −$5.0M | — | — | — | — | — | — | — |
| Financing activities | ||||||||||
| Dividends paid | −$246,005 | −$1.1M | −$22.5M | — | — | — | — | — | — | — |
| Share repurchases & issuance (net) | −$401,625 | −$25.0M | −$44.4M | −$13.6M | $0 | — | −$1 | — | $2.7M | $4.9M |
| Net borrowing (repayment) | — | — | — | $0 | −$50,805 | −$62,440 | $62,848 | $62,848 | $62,848 | $62,848 |
| Shares issued | $6.2M | $0 | $33.7M | $0 | $87.4M | $4.7M | $2.7M | $2.3M | $0 | $0 |
| Other financing | $1.0M | $1.1M | $22.5M | $880 | $0 | $0 | $0 | −$62,848 | −$62,848 | −$62,848 |
| Cash from financing activities | $6.6M | −$25.0M | −$10.7M | −$13.6M | $87.3M | $4.6M | $2.7M | $2.3M | $2.7M | $4.9M |
| Summary | ||||||||||
| Net change in cash | $3.4M | −$35.0M | −$17.9M | −$17.4M | $83.2M | $1.3M | $379,608 | −$544,545 | −$2.4M | $1.5M |
| Cash at end of period | $18.6M | $15.2M | $50.2M | $68.0M | $85.4M | $2.2M | $894,861 | $515,253 | $1.1M | $3.5M |
| Free cash flow | −$5.2M | −$3.0M | −$2.2M | −$3.8M | −$4.1M | −$3.3M | −$2.3M | −$2.9M | −$5.1M | −$3.3M |
| Operating cash flow / net income | — | −0.10 | −6.45 | — | — | — | — | — | — | — |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$5.1M | −$4.4M | $746,860 | −$7.4M | −$8.4M | $11.7M | −$3.0M | −$1.5M | $23.4M | $1.3M | −$619,537 | $2.8M |
| Stock-based compensation | $0 | $54,580 | $952,992 | $60,492 | $60,492 | $63,944 | $72,861 | $119,155 | $222,677 | $0 | $674,693 | $0 |
| Change in working capital | −$181,251 | −$1.1M | −$20,774 | $129,744 | −$954,840 | $1.3M | $422,205 | −$449,330 | $125,671 | $87,148 | $135,740 | −$554,610 |
| Other non-cash items | $4.5M | $4.0M | −$2.5M | $6.2M | $7.3M | −$14.1M | $2.0M | $745,000 | −$24.1M | −$1.8M | −$368,000 | −$4.2M |
| Cash from operating activities | −$780,894 | −$1.4M | −$786,848 | −$979,523 | −$2.0M | −$1.0M | −$509,893 | −$1.1M | −$373,297 | −$332,958 | −$177,104 | −$2.0M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | −$3 | −$5 | −$3 | $0 | −$4 | −$4 |
| Investments (net) | — | $0 | $0 | −$3.0M | $0 | $0 | $0 | $0 | −$7.0M | $0 | −$5.0M | $0 |
| Acquisitions & other investing | — | $2.00T | $5.0M | $0 | — | — | — | $7.0M | $3 | — | $4 | −$643,245 |
| Cash from investing activities | — | $2.00T | $5.0M | −$3.0M | — | — | — | $7.0M | −$7.0M | — | −$5.0M | −$643,249 |
| Financing activities | ||||||||||||
| Dividends paid | −$83,399 | −$246,005 | −$101,356 | −$61,250 | $0 | — | — | −$16.2M | −$22.46T | — | — | — |
| Share repurchases & issuance (net) | — | $223,856 | −$564,231 | −$61,250 | −$171,543 | −$171,543 | −$3.9M | −$10.7M | −$10.2M | −$10.7M | −$7.0M | −$164,953 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $0 | −$147,669 | $1.2M | $6.3M | $0 | $0 | $0 | $16.2M | $22.46T | $0 | $0 | $913,640 |
| Cash from financing activities | −$83,399 | −$169,818 | $543,779 | $6.2M | −$171,543 | −$171,543 | −$3.9M | −$10.7M | −$10.2M | −$10.7M | −$7.0M | $748,687 |
| Summary | ||||||||||||
| Net change in cash | −$864,908 | −$1.6M | $4.8M | $2.2M | −$2.0M | −$1.2M | −$4.5M | −$11.8M | −$17.5M | −$11.0M | −$12.2M | −$1.2M |
| Cash at end of period | $17.7M | $18.6M | $20.2M | $15.4M | $13.2M | $15.2M | $16.4M | $20.8M | $32.6M | $50.2M | $61.2M | $73.4M |
| Free cash flow | −$780,894 | −$1.4M | −$786,848 | −$979,523 | −$2.0M | −$1.0M | −$509,893 | −$1.1M | −$373,297 | −$332,958 | −$177,104 | −$2.0M |
| Operating cash flow / net income | — | — | −1.05 | — | — | −0.09 | — | — | −0.02 | −0.25 | — | −0.71 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
PMCB cash generation
In fiscal 2026 (ended April 30, 2026), PharmaCyte Biotech generated -$5.2 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$5.2 million. It returned $0.6 million to shareholders through dividends ($0.2 million) and net share buybacks ($0.4 million). Cash and equivalents rose by $3.4 million over the year.
Related: PMCB income statement, PMCB balance sheet. See the PMCB stock overview for the latest quote and news.
PMCB cash flow FAQ
What is PharmaCyte Biotech's free cash flow?
PharmaCyte Biotech's free cash flow was -$5.2 million in fiscal 2026: -$5.2 million of operating cash flow minus $0 of capital expenditures It was -$3.0 million a year earlier..
How much cash does PharmaCyte Biotech generate from operations?
PharmaCyte Biotech generated -$5.2 million of cash from operating activities in fiscal 2026.
How much stock does PharmaCyte Biotech buy back?
PharmaCyte Biotech spent $0.4 million on net share repurchases in fiscal 2026.
How much does PharmaCyte Biotech pay in dividends?
PharmaCyte Biotech paid $0.2 million in dividends in fiscal 2026.